<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-08-20T15:37:04Z</responseDate><request verb="GetRecord" identifier="oai:docta.ucm.es:20.500.14352/97650" metadataPrefix="qdc">https://docta.ucm.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:docta.ucm.es:20.500.14352/97650</identifier><datestamp>2025-03-18T12:25:43Z</datestamp><setSpec>com_20.500.14352_14</setSpec><setSpec>col_20.500.14352_15</setSpec></header><metadata><qdc:qualifieddc xmlns:qdc="http://dspace.org/qualifieddc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
   <dc:title>Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma</dc:title>
   <dc:creator>Oesch, Susanne</dc:creator>
   <dc:creator>Walter, Dagmar</dc:creator>
   <dc:creator>Wachtel, Marco</dc:creator>
   <dc:creator>Pretre, Kathya</dc:creator>
   <dc:creator>Salazar Roa, María</dc:creator>
   <dc:creator>Guzmán Pastor, Manuel</dc:creator>
   <dc:creator>Velasco Díez, Guillermo</dc:creator>
   <dc:creator>Schäfer, Beat </dc:creator>
   <dcterms:abstract>Gene expression profiling has revealed that the gene coding for cannabinoid receptor 1 (CB1) is highly up-regulated in rhabdomyosarcoma biopsies bearing the typical chromosomal translocations PAX3/FKHR or PAX7/FKHR. Because cannabinoid receptor agonists are capable of reducing proliferation and inducing apoptosis in diverse cancer cells such as glioma, breast cancer, and melanoma, we evaluated whether CB1 is a potential drug target in rhabdomyosarcoma. Our study shows that treatment with the cannabinoid receptor agonists HU210 and Δ9-tetrahydrocannabinol lowers the viability of translocation-positive rhabdomyosarcoma cells through the induction of apoptosis. This effect relies on inhibition of AKT signaling and induction of the stress-associated transcription factor p8 because small interfering RNA–mediated down-regulation of p8 rescued cell viability upon cannabinoid treatment. Finally, treatment of xenografts with HU210 led to a significant suppression of tumor growth in vivo. These results support the notion that cannabinoid receptor agonists could represent a novel targeted approach for treatment of translocation-positive rhabdomyosarcoma</dcterms:abstract>
   <dcterms:dateAccepted>2024-02-01T12:16:43Z</dcterms:dateAccepted>
   <dcterms:available>2024-02-01T12:16:43Z</dcterms:available>
   <dcterms:created>2024-02-01T12:16:43Z</dcterms:created>
   <dcterms:issued>2009</dcterms:issued>
   <dc:type>journal article</dc:type>
   <dc:identifier>https://hdl.handle.net/20.500.14352/97650</dc:identifier>
   <dc:identifier>1535-7163</dc:identifier>
   <dc:identifier>10.1158/1535-7163.MCT-08-1147</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>Susanne Oesch, Dagmar Walter, Marco Wachtel, Kathya Pretre, Maria Salazar, Manuel Guzmán, Guillermo Velasco, Beat W. Schäfer; Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. Mol Cancer Ther 1 July 2009; 8 (7): 1838–1845. https://doi.org/10.1158/1535-7163.MCT-08-1147</dc:relation>
   <dc:rights>restricted access</dc:rights>
   <dc:publisher>American Association Cancer Research</dc:publisher>
</qdc:qualifieddc></metadata></record></GetRecord></OAI-PMH>